The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Adults aged 18 or older
Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU
The participant or legally authorized representative must agree to the genetic analyses required as part of this study
Pregnant
Prisoner or in police custody
Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures
Hemoglobin less than 8 g/dL
Single group
13C6-Glucose
DrugCompounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams.
13C6-Glucose Uptake and Metabolism in Immune Cells
Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
